drugset / Trial / NCT01145846
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this non-inferiority study is to compare the effectiveness of two induction chemotherapy regimens (cytarabine plus idarubicin \[AI\] versus cytarabine plus high-dose daunorubicin \[AD\]) in AML. The effectiveness will be evaluated in terms of complete remission (CR) rate.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 1 g | Intravenous |
| Subject | Cytarabine | Small molecule | 3 g | Intravenous |
| Subject | Daunorubicin | Small molecule | 45 mg/m2 | Intravenous |
| Subject | Daunorubicin | Small molecule | 90 mg/m2 | Intravenous |